Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

A Compilation of Experiences in Utilizing CAR-T Cell Therapy for Richter's Transformation

Shaomei Feng, Teng Xu, Haidi Liu, Peihao Zheng, Lixia Ma, Hui SHI, Tong Wu, Fan Yang, Kai HU, Xiaoyan Ke

Blood (2023) 142 (Supplement 1): 4638.

https://doi.org/10.1182/blood-2023-182797

Published: 2023

Journal Articles

Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia

Wei Zhang, Li-xian Chang, Bei-bei Zhao, Dan-dan Shan, Bo-hao Tang, Fan Yang, Yue Zhou, Guo-xiang Hao, Yi Zheng, Ya-hui Zhang, John Van Den Anker, Xiaofan Zhu, Li Zhang, Wei Zhao

Blood (2023) 142 (Supplement 1): 1345.

https://doi.org/10.1182/blood-2023-181581

Published: 2023

Journal Articles

MASS-4 Is More Suitable Than MASS-3 for Prognostic Stratification in Transplant-Eligible Patients Withnewly Diagnosed Multiple Myeloma

Fan Yang, Juan Li

Blood (2023) 142 (Supplement 1): 4695.

https://doi.org/10.1182/blood-2023-173813

Published: 2023

Journal Articles

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

Fan Yang, Rui Liu, Teng Xu, Zhonghua Fu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui SHI, Lixia Ma, Guoai Su, Biping Deng, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 6922.

https://doi.org/10.1182/blood-2023-177836

Published: 2023

Journal Articles

CAR T- Cell Therapy Provides an Opportunity for Further Consolidation Treatment for Relapsed or Refractory Adult Burkitt Lymphoma Patients

Rui Liu, Fan Yang, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2023-184692

Published: 2023

Journal Articles

Evaluating the Impact of Cryopreservation of PBMCs on CAR-T Therapy Efficacy and Safety in DLBCL Patients: An Informative Approach to Optimize Manufacturing Strategies

Teng Xu, Fan Yang, Rui Liu, Zhonghua Fu, Na Li, Xiaoyan Ke, Shaomei Feng, Biping Deng, Kai Hu

Blood (2023) 142 (Supplement 1): 3513.

https://doi.org/10.1182/blood-2023-185590

Published: 2023

Journal Articles

G-CSF Use in Mobilization and Post-Hematopoietic Stem Cell Transplant Induces Regulatory Myeloid Populations

Erika McCartney, Shannon Snelling, Madison Denney, Raymond Kung, Marie Rachel, Zi Fan Yang, Qing Dong Guan, Karin G. Hermans, Donna A. Wall

Blood (2022) 140 (Supplement 1): 12659–12660.

https://doi.org/10.1182/blood-2022-170792

Published: 2022

Journal Articles

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Blood (2022) 140 (Supplement 1): 9637–9639.

https://doi.org/10.1182/blood-2022-168703

Published: 2022

Journal Articles

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Peihao Zheng, Rui Liu, Teng Xu, Fan Yang, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui Shi, Hongwei Yu, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2022) 140 (Supplement 1): 7548–7549.

https://doi.org/10.1182/blood-2022-168018

Published: 2022

Journal Articles

Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up

Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, Weijun Fu, Jianda Hu, Lijuan Chen, Yiwen Zhang, Dan Yao, Hui Li, Jordan M Schecter, Fan Yang, Huabin Sun, Sen Hong Zhuang, Da Xu, Tracy Luo, Xiaohu Fan, Ting Niu, Jie Jin, Sai-Juan Chen

Blood (2022) 140 (Supplement 1): 7542–7544.

https://doi.org/10.1182/blood-2022-159185

Published: 2022

Journal Articles

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Blood (2022) 140 (Supplement 1): 3891–3894.

https://doi.org/10.1182/blood-2022-168812

Published: 2022

Journal Articles

Interpreting Immune Reconstitution and Clinical Outcome By Single-Cell Transcriptomic Analysis in T-ALL Patients Undergoing Donor-Derived CD7 CAR-T Immunotherapy

Hui Shi, Kai Hu, Fan Yang, Zhuojun Liu, Jia Liu, Wei Chen, Jian Yu

Blood (2022) 140 (Supplement 1): 10422–10423.

https://doi.org/10.1182/blood-2022-165035

Published: 2022

Journal Articles

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Blood (2022) 140 (Supplement 1): 815–817.

https://doi.org/10.1182/blood-2022-166855

Published: 2022

Journal Articles

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Fan Yang, Rui Liu, Teng Xu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Tong Wu, Kai Hu

Blood (2022) 140 (Supplement 1): 10384–10385.

https://doi.org/10.1182/blood-2022-164446

Published: 2022

Journal Articles

Clinical Characteristics of Hemophagocytic Lymphohistiocytosis in Adults with Central Nervous System Involvement

Meng Li, Ai-lin Zhao, Lin-feng Li, Xin-ai Gan, Jin-rong Yang, Jie Wang, He Li, Kai Shen, Yun-fan Yang, Ting Niu

Blood (2022) 140 (Supplement 1): 11169.

https://doi.org/10.1182/blood-2022-167106

Published: 2022

Journal Articles

Combination of Haploidentical Hematopoietic with Low-Dose TBI and Cord Blood Transplantation for Hematologic Malignancies

Shenxian Qian, Fan Yang, Pengfei Shi

Blood (2021) 138 (Supplement 1): 4856.

https://doi.org/10.1182/blood-2021-152290

Published: 2021

Journal Articles

Better Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation with Reduced-Intensity Conditioning in Elderly Patients with Hematological Malignancies

Yongqiang Zhao, Yanzhi Song, Fan Yang, Feifei Li, Dongfang Yang, Tong Wu

Blood (2021) 138 (Supplement 1): 4864.

https://doi.org/10.1182/blood-2021-149871

Published: 2021

Journal Articles

Excellent Outcomes of the Second Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies with Reduced Toxicity Conditioning and Donor Change

Yongqiang Zhao, Yanzhi Song, Zhihui Li, Fan Yang, Feifei Li, Dongfang Yang, Tong Wu

Blood (2021) 138 (Supplement 1): 4891.

https://doi.org/10.1182/blood-2021-150087

Published: 2021

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning Including Donor Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma

Fan Yang, Hui Shi, Yang Lei, Ruiting Li, Teng Xu, Biping Deng, Tong Wu, Xiaoyan Ke, Kai Hu

Blood (2021) 138 (Supplement 1): 557.

https://doi.org/10.1182/blood-2021-146767

Published: 2021

Journal Articles

Allogeneic-Hematopoietic Stem Cell Transplantation Is Effective and Safe for Relapsed/ Refractory B-ALL Patients Who Cannot Get Remission or MRD Negative after CART Treatment

Yanzhi Song, Zhihui Li, Yongqiang Zhao, Fan Yang, Erhui Yuan, Qi Wang, Tong Wu

Blood (2021) 138 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2021-146357

Published: 2021

NARROW

A Compilation of Experiences in Utilizing CAR-T Cell Therapy for Richter's Transformation

Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia

MASS-4 Is More Suitable Than MASS-3 for Prognostic Stratification in Transplant-Eligible Patients Withnewly Diagnosed Multiple Myeloma

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

CAR T- Cell Therapy Provides an Opportunity for Further Consolidation Treatment for Relapsed or Refractory Adult Burkitt Lymphoma Patients

Evaluating the Impact of Cryopreservation of PBMCs on CAR-T Therapy Efficacy and Safety in DLBCL Patients: An Informative Approach to Optimize Manufacturing Strategies

G-CSF Use in Mobilization and Post-Hematopoietic Stem Cell Transplant Induces Regulatory Myeloid Populations

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Interpreting Immune Reconstitution and Clinical Outcome By Single-Cell Transcriptomic Analysis in T-ALL Patients Undergoing Donor-Derived CD7 CAR-T Immunotherapy

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Clinical Characteristics of Hemophagocytic Lymphohistiocytosis in Adults with Central Nervous System Involvement

Combination of Haploidentical Hematopoietic with Low-Dose TBI and Cord Blood Transplantation for Hematologic Malignancies

Better Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation with Reduced-Intensity Conditioning in Elderly Patients with Hematological Malignancies

Excellent Outcomes of the Second Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies with Reduced Toxicity Conditioning and Donor Change

Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning Including Donor Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma

Allogeneic-Hematopoietic Stem Cell Transplantation Is Effective and Safe for Relapsed/ Refractory B-ALL Patients Who Cannot Get Remission or MRD Negative after CART Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only